Musolino, A., Campone, M., Neven, P., Denduluri, N., Barrios, C. H., Cortes, J., . . . André, F. (2017). Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR(+), HER2(−) breast cancer that had progressed during or after prior endocrine therapy. Breast Cancer Res.
Stile di citazione ChicagoMusolino, Antonino, et al. "Phase II, Randomized, Placebo-controlled Study of Dovitinib in Combination With Fulvestrant in Postmenopausal Patients With HR(+), HER2(−) Breast Cancer That Had Progressed During or After Prior Endocrine Therapy." Breast Cancer Res 2017.
Citazione MLAMusolino, Antonino, et al. "Phase II, Randomized, Placebo-controlled Study of Dovitinib in Combination With Fulvestrant in Postmenopausal Patients With HR(+), HER2(−) Breast Cancer That Had Progressed During or After Prior Endocrine Therapy." Breast Cancer Res 2017.